[1]陈跃,黄占文,徐勇,等.加强多学科合作提高甲状腺疾病放射性核素治疗水平[J].国际放射医学核医学杂志,2008,32(6):357-359.
　CHEN Yue,HUANG Zhan-wen,XU Yong,et al.Intellectual co-operation on improving radionuclide therapy of thyroid disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(6):357-359.
点击复制

加强多学科合作提高甲状腺疾病放射性核素治疗水平(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
32
期数:
2008年第6期
页码:
357-359
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Intellectual co-operation on improving radionuclide therapy of thyroid disease
作者:
陈跃1;  黄占文1;  徐勇2;  张春银1;  朱建华2
1. 646000 四川, 四川泸州医学院附属医院核医学科;
2. 646000 四川, 四川泸州医学院附属医院内分泌科
Author(s):
CHEN Yue1;  HUANG Zhan-wen1;  XU Yong2;  ZHANG Chun yin1;  ZHU Jian-hu2
1. LDepartment of Nuclear Medicine, Luzhou 646000, China;
2. Department of Endocrinology, Affiliated Hospital of Luzfwu Medical College, Sichuan Luzhou 646000, China
关键词:
甲状腺疾病; 碘放射性同位素; 多学科合作
Keywords:
Thyroid diseases; Iodine radioisotopes; Intellectual co-operation
摘要:
甲状腺疾病足最常见的内分泌疾病,治疗手段包括内科、外科和核医学治疗方法。131I是甲状腺功能亢进症的重要治疗方法之一,重视多学科密切合作,可获得理想的治疗效果。
Abstract:
Thyroid disease is the most common endocrine disease. Treatment of thyroid disease includes the program of internal medicine, surgery and nuclear medicine. Radioactive iodine is one treatment of hyperthyroidism. Physician engaged in therapy with 131I should be able to collaborate closely with other physicians involved in the management of the Graves patient’s condition.

参考文献/References:

[1] Sisson JC,Schipper MJ,Nelson CC,et al. Radioiodine therapy and Graves’ ophthalmopathy[J]. J Nucl Med,2008,49(6):923-930.
[2] Cooper DS,Doherty GM,Haugen BR,et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid,2006,16(2):109-142.
[3] Erem C,Kandemir N,Hacihasanoglu A,et al. Radioiodine treatment of hyperthyroidism:prognostic factors affecting outcome[J]. Endocrine,2004,25(1):55-60.
[4] Metso S,Jaatinen P,Huhtala H,et al. Long-term follow-up study of radioiodine treatment of hyperthyroidism[J]. Clin Endocrinol,2004,61(5):641-648.
[5] 中华医学会.临床技术操作规范(核医学分册)[M].北京:人民军医出版社,2004:175-195.
[6] 滕卫平.甲状腺功能亢进症[M]//陆再英,钟南山.内科学.第7版.北京:人民卫生出版社,2008:712-721.
[7] 滕卫平.甲状腺功能亢进症[M]//叶任高,陆再英.内科学.第6版.北京:人民卫生出版社,2007:725-735.
[8] 廖二元.甲状腺功能亢进症[M]//叶任高,陆再英.内科学.第5版.北京:人民卫生出版社,2001:731-743.
[9] 陈跃,匡安仁.放射性核素治疗[M]//李少林,王荣福.核医学. 第7版[M].北京:人民卫生出版社,2008:145-153.
[10] 匡安仁.放射性核素治疗[M]//李少林.核医学.第6版.北京:人民卫生出版社,2007:233-264.
[11] 匡安仁.放射性核素治疗[M]//李少林.核医学.第5版.北京:人民卫生出版社,2002:337-382.
[12] 匡安仁,谭天秩.放射性核素治疗的发展与思考[J].中华核医学杂志,2003,23(6):325-326.
[13] 谭天秩.临床核医学[M].第2版.北京:人民卫生出版社社,2003:1284-1308.
[14] 刘剑锋,张友仁,邢家骝,等.131I治疗甲亢后早发甲低的临床分析[J].中华核医学杂志,2004,24(4):245-246.
[15] 满娜,李玉姝,滕卫平,等.亚临床甲状腺功能减退症患者的自身免疫特征及预后影响因素[J].中华内科杂志,2005,44(8):621-622.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
　Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[3]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[4]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[5]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[6]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[7]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[8]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[9]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[10]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[11]罗全勇,朱瑞森.rhTSH在甲状腺疾病治疗中的潜在价值[J].国际放射医学核医学杂志,2005,29(2):63.
　LUO Quan-yong,ZHU Rui-sen.Potential therapeutic uses for rhTSH in thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(6):63.
[12]陆克义,李险峰.甲状腺疾病患者131I治疗后对他人的辐射危害评价[J].国际放射医学核医学杂志,2004,28(5):226.
　LU Ke-yi,LI Xian-feng.Evaluation of radiation exposure from patients with thyroid disease by 131I therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(6):226.

备注/Memo

备注/Memo:
收稿日期:2008-09-18。
通讯作者:陈跃(E-mail:ohenyue5523@126.com)
更新日期/Last Update: 1900-01-01